Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1

Andrew Kuykendall, MD, reviews data from TRANSFORM-1 on navitoclax plus ruxolitinib for untreated myelofibrosis, highlighting consistent response rates, no significant symptom improvement with the combination, and challenges managing thrombocytopenia caused by navitoclax, despite its activity and potential as a second-line treatment option.

EP: 1.How JAK Inhibitors Have Shaped the Landscape of MF

EP: 2.Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2

Now Viewing

EP: 3.Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1

EP: 4.Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib

EP: 5.Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034

EP: 6.Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001

EP: 7.Future Directions in Combination Therapies for Myelofibrosis

EP: 8.Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF

EP: 9.The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib

EP: 10.Selection and Sequencing of JAK Inhibitors for Patients With MF

EP: 11.Individualizing Therapy Goals for Patients With Myelofibrosis

EP: 12.Emerging Treatments for Myelofibrosis

Related Videos

Related Content

Advertisement

March 12th 2025

Imetelstat Earns EU Approval for Transfusion-Dependent Anemia in Lower-Risk MDS

November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

March 11th 2025

Cema-Cel Induces CRs and Has Manageable Safety Profile in CD19 CAR T-Cell Therapy–Naive R/R LBCL

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

March 9th 2025

The OncFive: Top Oncology Articles for the Week of 3/2

March 6th 2025

Olverembatinib Plus Chemo Receives Breakthrough Therapy Designation in China for Newly Diagnosed Ph+ ALL

Related Content

Advertisement

March 12th 2025

Imetelstat Earns EU Approval for Transfusion-Dependent Anemia in Lower-Risk MDS

November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

March 11th 2025

Cema-Cel Induces CRs and Has Manageable Safety Profile in CD19 CAR T-Cell Therapy–Naive R/R LBCL

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

March 9th 2025

The OncFive: Top Oncology Articles for the Week of 3/2

March 6th 2025

Olverembatinib Plus Chemo Receives Breakthrough Therapy Designation in China for Newly Diagnosed Ph+ ALL